Primary systemic therapy for operable breast cancer - 10-year survival data after chemotherapy and hormone therapy

British Journal of Cancer

Volumn 76, Issue 8, 1997, Pages 1099-1105

  Cameron, D A ^a   Anderson, E D C ^a   Levack, P ^a   Hawkins, R A ^b   Anderson, T J ^b   Leonard, R C F ^a   Forrest, A P M ^b   Chetty, U ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

Chemotherapy; Early breast cancer; Hormone therapy; Preoperative systemic therapy; Response; Survival

Indexed keywords

AMINOGLUTETHIMIDE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; GOSERELIN; HORMONE; PREDNISOLONE; TAMOXIFEN; VINCRISTINE;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; FEMALE; FOLLOW UP; HORMONAL THERAPY; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PREOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; TREATMENT FAILURE;

EID: 0030880287     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.514     Document Type: Article

References (31)

1. Anderson EDC, Forrest APM, Levack PA, Chetty U and Hawkins RA (1989) Response to endocrine manipulation and oestrogen receptor concentration in large operable primary breast cancer. Br J Cancer 60: 223-226
2. Anderson EDC, Forrest APM, Hawkins RA, Anderson TJ, Leonard RCF and Chetty U (1991) Primary systemic therapy for operable breast cancer. Br J Cancer 63: 561-566
3. Bonadonna G, Veronesi U, Brambilla C, Ferrari L, Luini A, Greco M, Bartoli C, Coopmans De Yoldi G. Zucali R. Rilke F, Andreola S, Silvestrini R, Di Fronzo G and Valagussa P (1990) Primary chemotherapy to avoid mastectomy in tumours with diameters of three centimetres or more. J Natl Cancer Inst 82: 1539-1545
4. Bonadonna G, Valagussa P, Brambilla C and Ferrari L (1993) Preoperative chemotherapy in operable breast cancer. Lancet 341: 1485-1485
5. Bolti C, Vici P, Lopez M, Scinto AF, Cognetti F and Cavaliere R (1995) Prognostic value of lymph node metastases after neoadjuvant chemotherapy for large-sized operable carcinoma of the breast. J Am Coll Surg. 181: 202-208
6. Bélembaogo E, Feillel V, Chollet P, Curé, H. Verrelle, P. Kwiatkowski F, Acharc JL, Le Bouëdec G, Chassagne J, Bignon YJ, De Latour M, Lafaye C and Dauplat J (1992) Neoadjuvant chemotherapy in 126 operable breast cancers. Eur J Cancer 28A: 896-900
7. Calais G, Descamps P, Chapet S, Turgeon V, Reynaud-Bougnoux A, Lemarié E, Fignon A, Body G, Bougnoux P, Lansac J and Le Floch O (1993) Primary chemotherapy and radiosurgical breast-conserving treatment for patients with locally advanced operable breast cancer. Int J Radiat Oncol Biol Phys 26: 37-42
8. Cheung CWD and Johnson AE (1991) Carcinoma of the breast: measurement and the management of treatment. I. The value of the data. Br J Radiol 64: 29-36
9. Clarke RB, Laidlaw IJ, Jones LJ, Howell A and Anderson E (1993) Effect of tamoxifen on Ki67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor status. Br J Cancer 67: 606-611
10. Early Breast Cancer Trialists Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, systemic or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339: 1-14-271-85
11. Fisher B, Slack NH, Cross IDJ and Cooperating Investigators (1969) Cancer of the breast: size of neoplasm and prognosis. Cancer 24: 1071-1080
12. Fisher B, Rockette H, Robidoux A, Margolese R, Cruz A, Hoehn J, Boysen D, Mamounas E, Wickerham DL and Decillis A (1994) Effect of preoperative therapy for breast cancer (BC) on local-regional disease: first report of NSABP B-18 (abstract 57). Proc ASCO 13: 64
13. Forouhi P, Dixon JM, Leonard RCF and Chetty U (1995) Prospective randomized study of surgical morbidity following primary systemic therapy for breast cancer. Br J Surg 82: 79-82
14. Forrest APM, Levack PA, Chetty U, Hawkins RA, Miller WR, Smyth JF and Anderson TJ (1986) A human tumour model. Lancet 2: 840-842
15. Frye D, Buzdar A and Hortobagyi G (1995) Prognostic significance of axillary nodal involvement after preoperative chemotherapy in stage III breast cancer (abstract 81). Proc ASCO 14: 95
16. Gardin G, Rosson R, Campora E, Repetto L, Naso C, Canavese G, Catturich A, Corvò R, Guenzi M, Pronzato P, Baldini E and Conte PF (1995) Locally advanced non-metastatic breast cancer: analysis of prognostic factors in 125 patients homogeneously treated with a combined modality approach. Eur J Cancer 31A: 1428-1433
17. Gröhn P, Heinonen E, Klefström P and Tarkkanen J (1984) Adjuvant postoperative radiotherapy, chemotherapy, and immunotherapy in stage III breast cancer. Cancer 54: 670-674
18. Hawkins RA, Tesdale AL, Anderson EDC, Levack PA, Chetty U and Forrest APM (1990) Does the oestrogen receptor concentration of a breast cancer change during systemic therapy? Br J Cancer 61: 877-880
19. Horobin JM, Preece PE, Dewar JA, Wood RAB and Cuschieri A (1991) Long-term follow-up of elderly patients with locoregional breast cancer treated with tamoxifen only. Br J Surg 78: 213-217
20. Jacquillat C, Weil M, Baillet F, Borel C, Auclerc G, De Maublanc MA, Housset M, Forget G, Thill L, Soubrane C and Khayat D (1990) Results of neoadjuvant chemotherapy and radiation therapy in the breast-conserving treatment of 250 patients with all stages of infiltrative breast cancer. Cancer 66: 119-129
21. Keen J, Miller EP, Bellamy C, Dixon JM and Miller WR (1994) P-glycoprotein and resistance to tamoxifen. Lancet 343: 1047-1048
22. Mauriac L, Durand M, Avril A and Dilhuydy J-M (1991) Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumours larger than 3 cm. Ann Oncol 2: 347-354
23. Morrison JM, Howell A, Kelly KA, Grieve RJ, Monypenny IJ, Walker RA and Waterhouse JA (1989) West Midlands Oncology Association trials of adjuvant chemotherapy in operable breast cancer: results after a median follow-up of 7 years. 1. Patients with involved axillary lymph nodes. Br J Cancer 60: 911-918
24. Pichin MF, Broet P, Magde Enat H, Delarue JC, Spyratos F, Basuyay JP, Saez S, Rallet A, Courriere P, Millon R and Asselain B (1996) Prognostic value of steroid receptors after long-term follow-up of 2257 operable breast cancers. Br J Cancer 73: 1545-1551
25. Remvikos Y and Mosseri V, Zajdela A, Fourquet A, Durand JC, Pouillart P and Magdelenat H (1993) Prognostic value of the S-phase fraction of breast cancers treated by primary radiotherapy or neoadjuvant chemotherapy. Ann New York Acad Sci 698: 193-203
26. Scholl SM, Fourquet A, Asselain B, Pierga JY, Vicoq JR, Durand JC, Dorval T, Palangié T, Jouve M, Beuzeboc P, Garcio-Giratl E, Salmon RJ, De La Rochefordière A, Campana F and Pouillart P (1994) Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. Eur J Cancer 30A: 645-652
27. Scholl SM, Asselain B, Beuzchoc P, Pierga JY, Dorval T, Garcia-Giralt E, Jouve M, Palangié T, Fourquet A, Durand JC and Pouillart P (1995) Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for conserving surgery: an update (abstract P48). Anti-Cancer Drugs 6 (suppl. 2): 69
28. Scholl SM, Pierga JY, Asselain B, Buezeboc P, Dorval T, Garcia-Giralt E, Jouve M, Palangié T, Remvikos Y, Durand JC, Fourquet A and Pouillart P (1996) Breast tumour response to primary chemotherapy predicts local and distant control as well as survival. Eur J Cancer 31A: 1969-1975
29. Semiglazov VF, Topuzov EE, Bavli JL, Moiseyenko VM, Ivanova OA, Seleznev IK, Orlov AA, Barash NY, Golubeva OM and Chepic, OF (1994) Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIb-IIIa breast cancer. Ann Oncol 5: 591-595
30. Swenerton KD, Legha SS, Smith T, Hortobagyi GN, Gehan EA, Yap H, Gutterman JU and Blumenschein GR (1979) Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res 39: 1552-1562
31. Tormey DC, Gray R, Abeloff MD, Roseman DL, Gilchrist KW, Barylak EJ, Stott P and Falkson G 1992) Adjuvant therapy with a doxorubicin regimen and long-term tamoxifen in premenopausal breast cancer patients: an Eastern Cooperative Oncology Group trial. J Clin Oncol 10: 1848-1856